Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
© 2021. The Author(s)..
Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Communications biology - 4(2021), 1 vom: 29. Juli, Seite 926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Williams, Thomas L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1NHL2J4X8K |
|---|
| Anmerkungen: |
Date Completed 11.08.2021 Date Revised 03.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s42003-021-02453-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328710628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328710628 | ||
| 003 | DE-627 | ||
| 005 | 20240403232542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s42003-021-02453-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM328710628 | ||
| 035 | |a (NLM)34326460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Williams, Thomas L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2021 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a DX600 peptide |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Benztropine |2 NLM | |
| 650 | 7 | |a 1NHL2J4X8K |2 NLM | |
| 700 | 1 | |a Colzani, Maria T |e verfasserin |4 aut | |
| 700 | 1 | |a Macrae, Robyn G C |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Emma L |e verfasserin |4 aut | |
| 700 | 1 | |a Bloor, Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a Greenwood, Edward J D |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Jun Ru |e verfasserin |4 aut | |
| 700 | 1 | |a Strachan, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Kuc, Rhoda E |e verfasserin |4 aut | |
| 700 | 1 | |a Nyimanu, Duuamene |e verfasserin |4 aut | |
| 700 | 1 | |a Maguire, Janet J |e verfasserin |4 aut | |
| 700 | 1 | |a Lehner, Paul J |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Davenport, Anthony P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Communications biology |d 2018 |g 4(2021), 1 vom: 29. Juli, Seite 926 |w (DE-627)NLM284287245 |x 2399-3642 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2021 |g number:1 |g day:29 |g month:07 |g pages:926 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s42003-021-02453-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2021 |e 1 |b 29 |c 07 |h 926 | ||